Yuan Zhi
Stock Analyst at B. Riley Securities
(4.49)
# 1,097
Out of 5,060 analysts
133
Total ratings
40.9%
Success rate
19.1%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Initiated Coverage: Buy | $12 | $6.39 | +87.94% | 1 | Sep 25, 2026 | |
| LYEL Lyell Immunopharma | Reiterated: Buy | $44 | $8.15 | +439.88% | 2 | Sep 24, 2026 | |
| NUTX Nutex Health | Reiterated: Buy | $325 | $186.10 | +74.64% | 1 | Sep 4, 2026 | |
| LNTH Lantheus Holdings | Downgraded: Hold | $129 → $105 | $99.70 | +5.72% | 28 | Aug 18, 2026 | |
| HYPR Hyperfine | Reiterated: Buy | $2 → $1.6 | $0.7548 | +111.98% | 9 | Aug 10, 2026 | |
| STLN Starling Oncology | Reiterated: Buy | $6 → $11 | $6.43 | +71.07% | 3 | Aug 7, 2026 | |
| MIR Mirion Technologies | Reiterated: Buy | $29 | $15.15 | +91.42% | 11 | Jul 30, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $10 | $2.89 | +246.02% | 1 | Jun 25, 2026 | |
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $22.04 | +58.80% | 7 | Jun 9, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $68.80 | +20.64% | 6 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $4.53 | +76.60% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $13 | $2.17 | +499.08% | 13 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.86 | +437.63% | 2 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $16 | $1.03 | +1,453.40% | 6 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $4.11 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $1.13 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $16.84 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $34.09 | n/a | 12 | Feb 7, 2024 |
Precigen
Sep 25, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $6.39
Upside: +87.94%
Lyell Immunopharma
Sep 24, 2026
Reiterated: Buy
Price Target: $44
Current: $8.15
Upside: +439.88%
Nutex Health
Sep 4, 2026
Reiterated: Buy
Price Target: $325
Current: $186.10
Upside: +74.64%
Lantheus Holdings
Aug 18, 2026
Downgraded: Hold
Price Target: $129 → $105
Current: $99.70
Upside: +5.72%
Hyperfine
Aug 10, 2026
Reiterated: Buy
Price Target: $2 → $1.6
Current: $0.7548
Upside: +111.98%
Starling Oncology
Aug 7, 2026
Reiterated: Buy
Price Target: $6 → $11
Current: $6.43
Upside: +71.07%
Mirion Technologies
Jul 30, 2026
Reiterated: Buy
Price Target: $29
Current: $15.15
Upside: +91.42%
Whitehawk Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $2.89
Upside: +246.02%
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $22.04
Upside: +58.80%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $68.80
Upside: +20.64%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $4.53
Upside: +76.60%
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $2.17
Upside: +499.08%
Dec 17, 2025
Reiterated: Buy
Price Target: $10
Current: $1.86
Upside: +437.63%
Dec 16, 2025
Reiterated: Buy
Price Target: $13 → $16
Current: $1.03
Upside: +1,453.40%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $4.11
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $1.13
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $16.84
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $34.09
Upside: n/a